Elevated levels of brain homocysteine directly modulate the pathological phenotype of a mouse model of tauopathy

Abstract

A high circulating level of homocysteine (Hcy), also known as hyperhomocysteinemia, is a risk factor for Alzheimer’s disease (AD). Previous studies show that elevated Hcy promotes brain amyloidosis and behavioral deficits in mouse models of AD. However, whether it directly modulates the development of tau neuropathology independently of amyloid beta in vivo is unknown. Herein, we investigate the effect of diet-induced elevated levels of brain Hcy on the phenotype of a relevant mouse model of human tauopathy. Compared with controls, tau mice fed with low folate and B vitamins diet had a significant increase in brain Hcy levels and worsening of behavioral deficits. The same mice had a significant elevation of tau phosphorylation, synaptic pathology, and astrocytes activation. In vitro studies demonstrated that Hcy effect on tau phosphorylation was mediated by an upregulation of 5-lipoxygenase via cdk5 kinase pathway activation. Our findings support the novel concept that high Hcy level in the central nervous system is a metabolic risk factor for neurodegenerative diseases, specifically characterized by the progressive accumulation of tau pathology, namely tauopathies.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

References

  1. 1.

    Alzheimer’s Association. 2016 Alzheimer’s disease facts and figures. Alzheimer’s Dement. 2016;12:459–9.

    Article  Google Scholar 

  2. 2.

    Giannopoulos PG, Praticò D. Alzheimer’s disease. In: Colin RM, Victor, R, editors. Diet and Nutrition in Dementia and Cognitive Decline. London: Elsevier Publisher; 2005. p. 13–21.

  3. 3.

    Arendt T, Stieler JT, Holzer M. Tau and tauopathies. Brain Res Bull. 2016;126(Pt 3):238–92.

    CAS  Article  Google Scholar 

  4. 4.

    Spillantini MG, Goedert M. Tau pathology and neurodegeneration. Lancet Neurol. 2013;12:609–22.

    CAS  Article  Google Scholar 

  5. 5.

    Smith AD, Refsum H. Homocysteine, B vitamins, and cognitive impairment. Annu Rev Nutr. 2016;36:211–39.

    CAS  Article  Google Scholar 

  6. 6.

    Shen L, Ji HF. Associations between homocysteine, folic Acid, vitamin B12 and Alzheimer’s disease: insights from meta-analyses. J Alzheimers Dis. 2015;46:777–90.

    CAS  Article  Google Scholar 

  7. 7.

    Zhuo JM, Portugal GS, Kruger WD, Wang H, Gould TJ, Praticò D. Diet-induced hyperhomocysteinemia increases amyloid-beta formation and deposition in a mouse model of Alzheimer’s disease. Curr Alzheimer Res. 2010;7:140–9.

    CAS  Article  Google Scholar 

  8. 8.

    Fuso A, Nicolia V, Ricceri L, Cavallaro RA, Isopi E, Mangia F, et al. S-adenosylmethionine reduces the progress of the Alzheimer-like features induced by B-vitamin deficiency in mice. Neurobiol Aging. 2012;33:1482.e1–16.

    CAS  Article  Google Scholar 

  9. 9.

    Zhuo JM, Praticò D. Normalization of hyperhomocysteinemia improves cognitive deficits and ameliorates brain amyloidosis of a transgenic mouse model of Alzheimer’s disease. FASEB J. 2010;24:3895–902.

    CAS  Article  Google Scholar 

  10. 10.

    Suszyńska-Zajczyk J, Luczak M, Marczak L, Jakubowski H. Hyperhomocysteinemia and bleomycin hydrolase modulate the expression of mouse brain proteins involved in neurodegeneration. J Alzheimers Dis. 2014;40:713–26.

    Article  Google Scholar 

  11. 11.

    Li JG, Barrero C, Merali S, Praticò D. Homocysteine modulates 5-lipoxygenase expression level via DNA methylation. Aging Cell. 2017;16:273–80.

    CAS  Article  Google Scholar 

  12. 12.

    Andorfer C, Kress Y, Espinoza M, de Silva R, Tucker KL, Barde YA, et al. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem. 2003;86:582–90.

    CAS  Article  Google Scholar 

  13. 13.

    Li JG, Chu J, Barrero C, Merali S, Praticò D. Homocysteine exacerbates β-amyloid pathology, tau pathology, and cognitive deficit in a mouse model of Alzheimer disease with plaques and tangles. Ann Neurol. 2014;75:851–63.

    CAS  Article  Google Scholar 

  14. 14.

    Di Meco A, Lauretti E, Vagnozzi AN, Praticò D. Zileuton restores memory impairments and reverses amyloid and tau pathology in aged Alzheimer’s disease mice. Neurobiol Aging. 2014;35:2458–64.

    Article  Google Scholar 

  15. 15.

    Giannopoulos PF, Chu J, Sperow M, Li JG, Yu WH, Kirby LG, et al. Gene knockout of 5-lipoxygenase rescues synaptic dysfunction and improves memory in the triple-transgenic model of Alzheimer’s disease. Mol Psychiatry. 2014;19:511–8.

    CAS  Article  Google Scholar 

  16. 16.

    Vagnozzi AN, Giannopoulos PF, Praticò D. The direct role of 5-lipoxygenase on tau pathology, synaptic integrity and cognition in a mouse model of tauopathy. Transl Psychiatry. 2017;7:1288.

    Article  Google Scholar 

  17. 17.

    Giannopoulos PF, Chu J, Sperow M, Li JG, Yu WH, Kirby LG, et al. Pharmacologic inhibition of 5-lipoxygenase improves memory, rescues synaptic dysfunction, and ameliorates tau pathology in a transgenic model of tauopathy. Biol Psychiatry. 2015;78:693–701.

    CAS  Article  Google Scholar 

  18. 18.

    Moncada CA, Clarkson A, Perez-Leal O, Merali S. Mechanism and tissue specificity of nicotine-mediated lung S-adenosylmethionine reduction. J Biol Chem. 2008;283:7690–6.

    CAS  Article  Google Scholar 

  19. 19.

    Joshi YB, Giannopoulos PF, Chu J, Sperow M, Kirby LG, Abood ME, et al. Absence of ALOX5 gene prevents stress-induced memory deficits, synaptic dysfunction and tauopathy in a mouse model of Alzheimer’s disease. Hum Mol Genet. 2014;23:6894–902.

    CAS  Article  Google Scholar 

  20. 20.

    Chu J, Giannopoulos PF, Ceballos-Diaz C, Golde TE, Praticò D. 5-Lipoxygenase gene transfer worsens memory, amyloid, and tau brain pathologies in a mouse model of Alzheimer disease. Ann Neurol. 2012;72:442–54.

    CAS  Article  Google Scholar 

  21. 21.

    Chu J, Praticò D. Pharmacologic blockade of 5-lipoxygenase improves the amyloidotic phenotype of an Alzheimer’s disease transgenic mouse model involvement of γ-secretase. Am J Pathol. 2011;178:1762–9.

    CAS  Article  Google Scholar 

  22. 22.

    Chu J, Praticò D. 5-Lipoxygenase pharmacological blockade decreases tau phosphorylation in vivo: involvement of the cyclin-dependent kinase-5. Neurobiol Aging. 2013;34:1549–54.

    CAS  Article  Google Scholar 

  23. 23.

    McCully KS. Homocysteine metabolism, atherosclerosis, and diseases of aging. Compr Physiol. 2015;6:471–505.

    Article  Google Scholar 

  24. 24.

    Miwa K, Tanaka M, Okazaki S, Yagita Y, Sakaguchi M, Mochizuki H, et al. Increased total homocysteine levels predict the risk of incident dementia independent of cerebral small-vessel diseases and vascular risk factors. J Alzheimers Dis. 2016;49:503–13.

    CAS  Article  Google Scholar 

  25. 25.

    Aisen PS, Schneider LS, Sano M, Diaz-Arrastia R, van Dyck CH, Weiner MF, et al. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA. 2008;300:1774–83.

    CAS  Article  Google Scholar 

  26. 26.

    Pratico D. High-dose B vitamin supplements and Alzheimer disease. JAMA. 2009;301:1020–1.

    CAS  Article  Google Scholar 

  27. 27.

    Zhuo JM, Wang H, Praticò D. Is hyperhomocysteinemia an Alzheimer’s disease (AD) risk factor, an AD marker, or neither? Trends Pharmacol Sci. 2011;32:562–71.

    CAS  Article  Google Scholar 

  28. 28.

    Pacheco-Quinto J, Rodriguez de Turco EB, DeRosa S, Howard A, Cruz-Sanchez F, Sambamurti K, et al. Hyperhomocysteinemic Alzheimer’s mouse model of amyloidosis shows increased brain amyloid beta peptide levels. Neurobiol Dis. 2006;22:651–6.

    CAS  Article  Google Scholar 

  29. 29.

    Chung YC, Kruyer A, Yao Y, Feierman E, Richards A, Strickland S, et al. Hyperhomocysteinemia exacerbates Alzheimer’s disease pathology by way of the β-amyloid fibrinogen interaction. J Thromb Haemost. 2016;14:1442–52.

    CAS  Article  Google Scholar 

  30. 30.

    Li JG, Praticò D. High levels of homocysteine results in cerebral amyloid angiopathy in mice. J Alzheimers Dis. 2015;43:29–35.

    Article  Google Scholar 

  31. 31.

    Li JG, Merali S, Pratico D. Five lipoxygenase hypomethylation mediates the homocysteine effect on Alzheimer’s phenotype. Sci Rep. 2017;6:7. 46002

    Google Scholar 

  32. 32.

    Polydoro M, Acker CM, Duff K, Castillo PE, Davies P. Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. J Neurosci. 2009;29:10741–9.

    CAS  Article  Google Scholar 

  33. 33.

    Li JG, Barrero C, Merali S, Praticò D. Genetic absence of ALOX5 protects from homocysteine-induced memory impairment, tau phosphorylation and synaptic pathology. Hum Mol Genet. 2017;26:1855–62.

    CAS  Article  Google Scholar 

Download references

Acknowledgements

Domenico Praticò is the Scott Richards North Star Charitable Foundation Chair for Alzheime'rs research. The work presented in this paper was in part supported by grants from the National Institute of Health (HL112966 and AG51684).

Author contributions:

ADM and DP designed the study; ADM and JGL performed the experiments; CB and SM were involved in the measurement of Hcy SAM an SAH; ADM and DP analyzed the data and drafted the manuscript. All authors have discussed the results and seen the final version of the paper before submission.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Domenico Praticò.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Di Meco, A., Li, J., Barrero, C. et al. Elevated levels of brain homocysteine directly modulate the pathological phenotype of a mouse model of tauopathy. Mol Psychiatry 24, 1696–1706 (2019). https://doi.org/10.1038/s41380-018-0062-0

Download citation

Further reading